Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Shigeo Taniuchi to Become CEO of Santen
March 16, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
- Daicel, AnGes/Osaka Univ. to Collaborate in Developing COVID-19 Vaccine
March 16, 2020
- PeptiDream, Mitsubishi to Launch JV to Develop Peptide Alternatives to Cell Culture Growth Factors
March 16, 2020
- Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
- Medicago Successfully Produces COVID-19 Vaccine Candidate
March 13, 2020
- Sanofi Exploring Kevzara Use for Novel Coronavirus
March 13, 2020
- Pfizer Japan Delivers 1.1% Growth in FY2019
March 13, 2020
- Artz Battered by Deep Reduction as “G2” Price Cut Applied for Second Time
March 12, 2020
- Ninlaro Misses Primary Goal in Front-Line Myeloma Study
March 12, 2020
- Nipro Confirms Coronavirus Infection Case at Niigata Branch
March 12, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Santen Calls Off Development of wAMD Treatment after PIIa Fails
March 12, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Singapore
March 12, 2020
- Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
- Relugolix Combo Tablet Filed in EU for Uterine Fibroids
March 11, 2020
- Janssen Files for Darzalex in Japan for Combo Therapy with Carfilzomib, Dexamethasone
March 11, 2020
- Medipal Forms Capital and Business Alliance with Cardiac Regenerative Medicine Startup
March 11, 2020
- Pfizer Most Affected by G1 Rule, 8 Off-Patent APIs Go into This Category: Jiho Survey
March 10, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…